Aurion Biotech, a biotechnology company specializing in developing vision restoration therapies, has appointed leading cornea, cataract, and refractive surgeon Marjan Farid as chair of its medical advisory board (MAB).
Farid currently serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California, Irvine (UCI). She is also Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS).
According to Aurion, Farid will help guide the company’s clinical and strategic direction as it expands development of regenerative therapies for corneal disease.
“Aurion is on the cusp of transforming corneal care in the United States,” Farid said in a statement. “I’m honored to be part of this incredible endeavor to bring a potential cure for blindness caused by corneal endothelial disease.”
Aurion is currently developing AURN001, an investigational single-administration, allogeneic cell therapy for corneal endothelial disease, a condition that leads to progressive vision loss and affects millions of patients globally. The therapy is currently in Phase 3 clinical development in the US.
The company already markets a related therapy in Japan. In 2024, Aurion launched Vyznova, described as the first commercially available cell therapy for corneal endothelial disease.
Aurion’s Chief Medical Officer, Edward J. Holland, said Farid’s appointment brings a highly respected clinical voice to the company’s advisory leadership.
“Dr. Farid has spent her career advancing patient care, driving innovation, and informing strategic decision-making,” Holland said. “Her expertise will complement Aurion’s MAB as we grow our pipeline of transformative regenerative medicines.”
Farid is widely recognized for her work in corneal and ocular surface disease. At UCI she established the Severe Ocular Surface Disease Program, a Holland Foundation–supported Center of Excellence focused on advanced treatment and research in the field, and her clinical expertise spans refractive and cataract surgery, complex intraocular lens procedures, and corneal and ocular surface transplantation.
Source: Business Wire.
Farid currently serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California, Irvine (UCI). She is also Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS).
According to Aurion, Farid will help guide the company’s clinical and strategic direction as it expands development of regenerative therapies for corneal disease.
“Aurion is on the cusp of transforming corneal care in the United States,” Farid said in a statement. “I’m honored to be part of this incredible endeavor to bring a potential cure for blindness caused by corneal endothelial disease.”
Aurion is currently developing AURN001, an investigational single-administration, allogeneic cell therapy for corneal endothelial disease, a condition that leads to progressive vision loss and affects millions of patients globally. The therapy is currently in Phase 3 clinical development in the US.
The company already markets a related therapy in Japan. In 2024, Aurion launched Vyznova, described as the first commercially available cell therapy for corneal endothelial disease.
Aurion’s Chief Medical Officer, Edward J. Holland, said Farid’s appointment brings a highly respected clinical voice to the company’s advisory leadership.
“Dr. Farid has spent her career advancing patient care, driving innovation, and informing strategic decision-making,” Holland said. “Her expertise will complement Aurion’s MAB as we grow our pipeline of transformative regenerative medicines.”
Farid is widely recognized for her work in corneal and ocular surface disease. At UCI she established the Severe Ocular Surface Disease Program, a Holland Foundation–supported Center of Excellence focused on advanced treatment and research in the field, and her clinical expertise spans refractive and cataract surgery, complex intraocular lens procedures, and corneal and ocular surface transplantation.
Source: Business Wire.
